Bromerguride (INNTooltip International Nonproprietary Name), also known as 2-bromolisuride, is an antidopaminergic and serotonergic agent of the ergoline group which was described as having atypical antipsychotic properties but was never marketed.[1][2][3][4][5] It was the first antidopaminergic ergoline derivative to be discovered.[1] The pharmacodynamic actions of bromerguride are said to be "reversed"[jargon] relative to its parent compound lisuride, a dopaminergic agent.[6]

References

  1. ^ a b Wachtel H, Kehr W, Sauer G (December 1983). "Central antidopaminergic properties of 2-bromolisuride, an analogue of the ergot dopamine agonist lisuride". Life Sci. 33 (26): 2583–97. doi:10.1016/0024-3205(83)90342-9. PMID 6607392.
  2. ^ Krause W, Sauerbrey N, Gräf KJ (1986). "Pharmacokinetics and pharmacodynamics in man of the dopamine antagonist ergot derivative, bromerguride". Eur J Clin Pharmacol. 31 (2): 165–8. doi:10.1007/BF00606653. PMID 3803415. S2CID 25185807.
  3. ^ Fink H, Morgenstern R, Ott T (February 1991). "2-Bromolisuride, an ergot derivative, with dopamine antagonistic and serotonin agonistic properties". Pharmacol Biochem Behav. 38 (2): 321–5. doi:10.1016/0091-3057(91)90285-a. PMID 1905409. S2CID 46024181.
  4. ^ Assié MB, Cosi C, Koek W (September 1997). "5-HT1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine". Eur J Pharmacol. 334 (2–3): 141–7. doi:10.1016/s0014-2999(97)01207-7. PMID 9369342.
  5. ^ Löschmann PA, Horowski R, Wachtel H (1992). "Bromerguride--an ergoline derivative with atypical neuroleptic properties". Clin Neuropharmacol. 15 Suppl 1 Pt A: 263A–264A. doi:10.1097/00002826-199201001-00137. PMID 1354031. S2CID 34842719.
  6. ^ Hilderbrand M, Hümpel M, Krause W, Täuber U (1987). "Pharmacokinetics of bromerguride, a new dopamine-antagonistic ergot derivative in rat and dog". Eur J Drug Metab Pharmacokinet. 12 (1): 31–40. doi:10.1007/BF03189859. PMID 3609071. S2CID 22838914.